Granulomatoz Polianjiitis Tanisi Alan Hastada Es Zamanli Covid-19 ve Hizli Ilerleyen Glomerulonefrit Yonetimi Olgu Sunumu

Abstract

Granulomatous polyangiosis (GPA) is a systemic necrotizing granulomatous vasculitis effected the upper-lower airways and the kidney. Small and middle diameter arteries are involved, especially. It is the one of the ANCA associated vasculitis and its characteristic pathological finding is the formation of granulomas. Female and male are affected approximately equally and the average diagnosis is around 40-50 years old. The main symptoms are fever, weakness, sweating, weight loss, myalgia, arthralgia. Respiratory tract, lung, kidney, skin and peripheral nerve involvement are observed. Pulmonary-renal failure, infection and treatment side effects are causes of mortality. Recently, while the coronavirus disease-19 (COVID-19) pandemic continues, data on covid treatment and how the process of the disease will go is very limited in vasculitis patients. Information on how to continue immunosuppressive therapy during COVID-19 infection is also not clear enough. Herein, we reported as a case of our patient who was newly diagnosed with GPA was infected with COVID-19 while receiving induction methylprednisolone and cyclophosphamide therapy, and clinically significant improvement was observed when induction therapy was continued even while receiving COVID-19 therapy.